AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Summary

AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.

Timeline

Start

2015-04-27

Primary completion

2016-09-19

Completion

2016-09-19

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Placebo vs AZD3241 300 mg; p = 0.32; Mean Difference (Final Values) 0.35; ANOVA; note: no adjustment NCT02388295 ↗

registry analysis (superiority or other test); Placebo vs AZD3241 600 mg; p = 0.45; Mean Difference (Final Values) 0.28; ANOVA; note: no adjustment NCT02388295 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Verdiperstat	Small molecule	—	Oral

Indications